A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

subcutaneous, single dose 0.3 mg/kg

Subcutaneous normal saline single dose

Subcutaneous, single dose 1.0 mg/kg

Subcutaneous normal saline single dose

Subcutaneous single dose 3 mg/kg

Subcutaneous normal saline single dose

Subcutaneous single dose 6 mg/kg

Subcutaneous normal saline single dose

Intravenous infusion single dose 1 mg/kg

Intravenous infusion normal saline single dose

Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)

Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)

Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)

Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)

Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)

Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)

Subcutaneous injection multiple dose TBD mg (Days TBD)

Subcutaneous injection normal saline multiple dose (Days TBD)